DUBLIN - Sunday, August 11th 2013 [ME NewsWire]
Third quarter net sales of $570 million, up 10.4%, versus prior-year quarter
Third quarter specialty pharmaceuticals net sales of $309 million rose 21.2%
Third quarter loss per share of $0.48; excluding specified items, adjusted earnings per share(1) of $0.49
Three year, $100 million to $125 million restructuring program announced
(BUSINESS WIRE) Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals and global medical imaging business, today reported results for the third quarter of fiscal 2013, ended June 28, 2013.
Net sales were $570.0 million for the third fiscal quarter of 2013, an increase of 10.4%, compared with $516.3 million reported in the third quarter of fiscal 2012.
On a non-GAAP basis, adjusted net income(1) for the third fiscal quarter of 2013 was $28.4 million, compared with $50.6 million a yea
Read more »